These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 20490813)

  • 1. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.
    Urwin H; Josephs KA; Rohrer JD; Mackenzie IR; Neumann M; Authier A; Seelaar H; Van Swieten JC; Brown JM; Johannsen P; Nielsen JE; Holm IE; ; Dickson DW; Rademakers R; Graff-Radford NR; Parisi JE; Petersen RC; Hatanpaa KJ; White CL; Weiner MF; Geser F; Van Deerlin VM; Trojanowski JQ; Miller BL; Seeley WW; van der Zee J; Kumar-Singh S; Engelborghs S; De Deyn PP; Van Broeckhoven C; Bigio EH; Deng HX; Halliday GM; Kril JJ; Munoz DG; Mann DM; Pickering-Brown SM; Doodeman V; Adamson G; Ghazi-Noori S; Fisher EM; Holton JL; Revesz T; Rossor MN; Collinge J; Mead S; Isaacs AM
    Acta Neuropathol; 2010 Jul; 120(1):33-41. PubMed ID: 20490813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
    Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
    Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
    Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
    J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.
    A Armstrong R
    Folia Neuropathol; 2017; 55(3):185-192. PubMed ID: 28984110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct pathological subtypes of FTLD-FUS.
    Mackenzie IR; Munoz DG; Kusaka H; Yokota O; Ishihara K; Roeber S; Kretzschmar HA; Cairns NJ; Neumann M
    Acta Neuropathol; 2011 Feb; 121(2):207-18. PubMed ID: 21052700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in wasteosomes (corpora amylacea) in frontotemporal lobar degeneration with specific detection of tau, TDP-43 and FUS pathology.
    Alsina R; Riba M; Pérez-Millan A; Borrego-Écija S; Aldecoa I; Romera C; Balasa M; Antonell A; Lladó A; Compta Y; Del Valle J; Sánchez-Valle R; Pelegrí C; Molina-Porcel L; Vilaplana J
    Acta Neuropathol Commun; 2024 Jun; 12(1):97. PubMed ID: 38879502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
    Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
    Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the Phenotype of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FUS).
    Chornenka K; Hirsch-Reinshagen V; Perez-Rosendahl M; Feldman H; Segal-Gidan F; Vinters HV; Mackenzie IR
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):809-812. PubMed ID: 32483606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS.
    Josephs KA; Whitwell JL; Parisi JE; Petersen RC; Boeve BF; Jack CR; Dickson DW
    Eur J Neurol; 2010 Jul; 17(7):969-75. PubMed ID: 20236174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration.
    Hofmann JW; Seeley WW; Huang EJ
    Annu Rev Pathol; 2019 Jan; 14():469-495. PubMed ID: 30355151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontotemporal lobar degeneration: diversity of FTLD lesions.
    Seilhean D; Bielle F; Plu I; Duyckaerts C
    Rev Neurol (Paris); 2013 Oct; 169(10):786-92. PubMed ID: 24035575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD).
    Lourenco GF; Janitz M; Huang Y; Halliday GM
    Neurobiol Dis; 2015 Oct; 82():445-454. PubMed ID: 26220395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration.
    Kawakami I; Kobayashi Z; Arai T; Yokota O; Nonaka T; Aoki N; Niizato K; Oshima K; Higashi S; Katsuse O; Hosokawa M; Hasegawa M; Akiyama H
    Acta Neuropathol Commun; 2016 Apr; 4():36. PubMed ID: 27044537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43.
    Mackenzie IR; Neumann M; Cairns NJ; Munoz DG; Isaacs AM
    J Mol Neurosci; 2011 Nov; 45(3):402-8. PubMed ID: 21603977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
    Davidson YS; Robinson AC; Hu Q; Mishra M; Baborie A; Jaros E; Perry RH; Cairns NJ; Richardson A; Gerhard A; Neary D; Snowden JS; Bigio EH; Mann DM
    Neuropathol Appl Neurobiol; 2013 Feb; 39(2):157-65. PubMed ID: 22497712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The molecular pathology of frontotemporal lobar degeneration].
    Fujishiro H; Hasegawa M; Arai T
    Seishin Shinkeigaku Zasshi; 2010; 112(4):313-24. PubMed ID: 20496755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies.
    Koga S; Murakami A; Soto-Beasley AI; Walton RL; Baker MC; Castanedes-Casey M; Josephs KA; Ross OA; Dickson DW
    Acta Neuropathol Commun; 2023 Jul; 11(1):109. PubMed ID: 37415197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Argyrophilic Grain Pathology in Frontotemporal Lobar Degeneration: Demographic, Clinical, Neuropathological, and Genetic Features.
    Gil MJ; Manzano MS; Cuadrado ML; Fernández C; Góméz E; Matesanz C; Calero M; Rábano A
    J Alzheimers Dis; 2018; 63(3):1109-1117. PubMed ID: 29758948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct early symptoms in neuropathologically proven frontotemporal lobar degeneration.
    Kawakami I; Arai T; Shinagawa S; Niizato K; Oshima K; Ikeda M
    Int J Geriatr Psychiatry; 2021 Jan; 36(1):38-45. PubMed ID: 32748432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration.
    Rohrer JD; Lashley T; Schott JM; Warren JE; Mead S; Isaacs AM; Beck J; Hardy J; de Silva R; Warrington E; Troakes C; Al-Sarraj S; King A; Borroni B; Clarkson MJ; Ourselin S; Holton JL; Fox NC; Revesz T; Rossor MN; Warren JD
    Brain; 2011 Sep; 134(Pt 9):2565-81. PubMed ID: 21908872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.